In order to identify biomarkers for earlier prediction of COVID-19 outcome, we collected blood samples from patients with fatal outcomes (non-survivors) and with positive clinical outcomes (survivors)
Tissue proteomics is increasingly recognized for its role in biomarker discovery and disease mechanism investigation. However, protein solubility remains a significant challenge in mass spectrometry (
We have included human samples including bladder tissue, Cervical tissue, Colorectal tissue, diffuse large B-cell lymphoma, Gastric tissue, glioblastoma multiforme, K562 cell, thyroid tissue, Plasma,
